Yondelis® Is An Important Treatment Option For Soft Tissue Sarcoma .
Commercialization To Begin Summer 2020 .
MONTREAL , June 8, 2020 /CNW Telbec/ .
Valeo Pharma Inc. (VPH.CN) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has received a Notice of Compliance from Health Canada authorizing the transfer of the commercial rights of Yondelis® to Valeo. Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain .
"With the receipt of Health Canada's approval, Valeo can now assume the commercialization of Yondelis® in Canada . Yondelis® is an important treatment option for patients with soft tissue sarcoma and represents a key addition to our specialty product portfolio", said Steve Saviuk , Valeo's President and CEO. "Yondelis® is the first of five product approvals and launches that we anticipate over the second half of the year. We expect that these launches will be materially accretive to our revenues and profitability".
